## **Trimazosin**

Cat. No.: HY-106554 CAS No.: 35795-16-5 Molecular Formula:  $C_{20}H_{29}N_5O_6$  Molecular Weight: 435.47

Target: Adrenergic Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

**Product** Data Sheet

## **BIOLOGICAL ACTIVITY**

Description	Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block $\alpha$ 1-adrenoceptors <sup>[1][2]</sup> .	
IC <sub>50</sub> & Target	lpha1-adrenergic receptor	
In Vivo	Trimazosin (10–30 mg/kg; i.h.; once) produces graded decreases in blood pressure <sup>[3]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Conscious spontaneously hypertensive rats (SHR) <sup>[3]</sup>
	Dosage:	10–30 mg/kg
	Administration:	Subcutaneous administration, once
	Result:	Produced graded decreases in blood pressure.

## **REFERENCES**

[1]. J. P. Buyniski, et al. Effects of Tiodazosin, Prazosin, Trimazosin and Phentolamine on Blood Pressure, Heart Rate and on Pre- and Postsynaptic  $\alpha$ -Adrenergic Receptors in the Rat. Clinical and Experimental Hypertension , 1980, Vol.2(6), p.1039-1066.

[2]. J Vincent, et al. The cardiovascular effects of trimazosin and prazosin in the rabbit. Clin Exp Pharmacol Physiol. 1986 Aug;13(8):593-608.

 $\hbox{[3]. HL\,Elliott, et al.\,Trimazosin\,in\,normotensive\,subjects.\,Clin\,Pharmacol\,Ther.\,1984\,Feb;} 35(2):156-60.$ 

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 1 www.MedChemExpress.com